99% Savings - Buy Just @1 Rs X
Nebycare 2.5 Tablet is a commercial drug that is prescribed in the form of Tablet. It is typically used for the treatment of High BP.
The correct dosage of Nebycare 2.5 Tablet depends on the patient's age, gender, and medical history. The condition it has been prescribed for, and the route of administration also determine the right dosage. For detailed information on this, read through the dosage section.
While these are the most often observed Nebycare 2.5 Tablet side effects, there are can be others also. These have been listed below. These side effects of Nebycare 2.5 Tablet are usually temporary and subside with the completion of treatment. Consult your doctor if these side effects become worse or stay for a longer duration.
It is also important to note that Nebycare 2.5 Tablet has a Severe effect for pregnant women and Severe effect on lactating mothers. In addition, Nebycare 2.5 Tablet's effects on the liver, heart and kidney are discussed below in the Nebycare 2.5 Tablet related warnings section.
Nebycare 2.5 Tablet can cause adverse effects in certain medical conditions. It is strongly recommended to avoid Nebycare 2.5 Tablet in conditions like Diabetes, Asthma, COPD (Chronic Obstructive Pulmonary Disease). The section on Nebycare 2.5 Tablet contraindications lists all such conditions.
Besides this, Nebycare 2.5 Tablet may also have severe interaction with some medicines. A complete list of these interactions is given below.
In addition to these precautions, you may also note that Nebycare 2.5 Tablet is not safe while driving, and is is not addictive in nature.
Nebycare 2.5 Tablet is used to treat the following -
Main Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult |
|
Geriatric |
|
Is the use of Nebycare 2.5 Tablet safe for pregnant women?
Pregnant women may get severe side effects after taking Nebycare. If you are pregnant, do not take Nebycare without a doctor's advice.
Is the use of Nebycare 2.5 Tablet safe during breastfeeding?
Nebycare should not be taken without taking your doctor's advice, as it may have severe side effects on breastfeeding women.
What is the effect of Nebycare 2.5 Tablet on the Kidneys?
Nebycare may have mild side effects on the kidneys.
What is the effect of Nebycare 2.5 Tablet on the Liver?
Side effects of Nebycare rarely affect the liver.
What is the effect of Nebycare 2.5 Tablet on the Heart?
Side effects of Nebycare rarely affect the heart.
If you are suffering from any of the following diseases, you should not take Nebycare 2.5 Tablet unless your doctor advises you to do so -
Is this Nebycare 2.5 Tablet habit forming or addictive?
Forming a habit of Nebycare 2.5 Tablet has not been reported.
Is it safe to drive or operate heavy machinery when consuming?
You may feel sleepy or tired after taking Nebycare 2.5 Tablet. So it is best to avoid driving.
Is it safe?
Nebycare 2.5 Tablet is safe but it is important to consult a doctor before taking it.
Is it able to treat mental disorders?
No, Nebycare 2.5 Tablet is not used to treat mental disorders.
Interaction between Food and Nebycare 2.5 Tablet
Eating certain foods may increase the time it takes Nebycare 2.5 Tablet to have an effect. You should consult your doctor about it.
Interaction between Alcohol and Nebycare 2.5 Tablet
Consuming Nebycare 2.5 Tablet with alcohol can have many serious effects on your body.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Bystolic® (nebivolol)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 149-151
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 896-897